Elevation Oncology (ELEV) Files 6.25M Share IPO at $15-$17/sh

Elevation Oncology (NASDAQ: ELEV) has filed to IPO 6.25M shares at $15-$17 per share.

ELEV is a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. It is focused on identifying oncogenic drivers that are known to be predominantly mutually exclusive with other driver alterations and pursuing innovations and efficiencies in the conduct of clinical trials that they believe may enable development of targeted therapeutics against those oncogenic drivers.

JP Morgan, Cowen and SVB Leerink will serve as underwriters.

You May Also Be Interested In

• Suja Life refinances credit agreement, cuts borrowing spread
• LiveRamp shrinks board to six directors after resignation
• Veeva Systems names Dan Rizzo EVP of sales amid leadership change